GB202020191D0 - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds

Info

Publication number
GB202020191D0
GB202020191D0 GBGB2020191.9A GB202020191A GB202020191D0 GB 202020191 D0 GB202020191 D0 GB 202020191D0 GB 202020191 A GB202020191 A GB 202020191A GB 202020191 D0 GB202020191 D0 GB 202020191D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2020191.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Priority to GBGB2020191.9A priority Critical patent/GB202020191D0/en
Publication of GB202020191D0 publication Critical patent/GB202020191D0/en
Priority to MX2023007140A priority patent/MX2023007140A/es
Priority to PE2023001903A priority patent/PE20240646A1/es
Priority to AU2021404194A priority patent/AU2021404194A1/en
Priority to CR20230256A priority patent/CR20230256A/es
Priority to IL303484A priority patent/IL303484A/en
Priority to EP21836606.0A priority patent/EP4263536A1/en
Priority to KR1020237023911A priority patent/KR20230121830A/ko
Priority to JP2023536899A priority patent/JP7730369B2/ja
Priority to CA3202054A priority patent/CA3202054A1/en
Priority to PCT/GB2021/053372 priority patent/WO2022129951A1/en
Priority to CN202180093050.7A priority patent/CN116848109B/zh
Priority to US17/874,564 priority patent/US11999745B2/en
Priority to JOJO/P/2023/0128A priority patent/JOP20230128A1/ar
Priority to ZA2023/06305A priority patent/ZA202306305B/en
Priority to DO2023000125A priority patent/DOP2023000125A/es
Priority to CL2023001755A priority patent/CL2023001755A1/es
Priority to CONC2023/0007838A priority patent/CO2023007838A2/es
Priority to ECSENADI202344370A priority patent/ECSP23044370A/es
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB2020191.9A 2019-04-23 2020-12-18 Pharmaceutical compounds Ceased GB202020191D0 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
GBGB2020191.9A GB202020191D0 (en) 2020-12-18 2020-12-18 Pharmaceutical compounds
CN202180093050.7A CN116848109B (zh) 2020-12-18 2021-12-20 药物化合物
JP2023536899A JP7730369B2 (ja) 2020-12-18 2021-12-20 医薬化合物
PCT/GB2021/053372 WO2022129951A1 (en) 2020-12-18 2021-12-20 Pharmaceutical compounds
AU2021404194A AU2021404194A1 (en) 2020-12-18 2021-12-20 Pharmaceutical compounds
CR20230256A CR20230256A (es) 2020-12-18 2021-12-20 Compuestos farmacéuticos
IL303484A IL303484A (en) 2020-12-18 2021-12-20 Pharmaceutical compounds
EP21836606.0A EP4263536A1 (en) 2020-12-18 2021-12-20 Pharmaceutical compounds
KR1020237023911A KR20230121830A (ko) 2020-12-18 2021-12-20 제약 화합물
MX2023007140A MX2023007140A (es) 2020-12-18 2021-12-20 Compuestos farmaceuticos.
CA3202054A CA3202054A1 (en) 2020-12-18 2021-12-20 Pharmaceutical compounds
PE2023001903A PE20240646A1 (es) 2020-12-18 2021-12-20 Compuestos farmaceuticos
US17/874,564 US11999745B2 (en) 2020-12-18 2022-07-27 Pharmaceutical compounds
JOJO/P/2023/0128A JOP20230128A1 (ar) 2020-12-18 2023-06-06 مركبات صيدلانية
ZA2023/06305A ZA202306305B (en) 2019-04-23 2023-06-15 Pharmaceutical compounds
DO2023000125A DOP2023000125A (es) 2020-12-18 2023-06-15 Compuestos farmacéuticos
CL2023001755A CL2023001755A1 (es) 2020-12-18 2023-06-15 Compuestos farmacéuticos.
CONC2023/0007838A CO2023007838A2 (es) 2020-12-18 2023-06-15 Compuestos farmacéuticos
ECSENADI202344370A ECSP23044370A (es) 2020-12-18 2023-06-15 Compuestos farmacéuticos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2020191.9A GB202020191D0 (en) 2020-12-18 2020-12-18 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
GB202020191D0 true GB202020191D0 (en) 2021-02-03

Family

ID=74221349

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2020191.9A Ceased GB202020191D0 (en) 2019-04-23 2020-12-18 Pharmaceutical compounds

Country Status (18)

Country Link
US (1) US11999745B2 (enExample)
EP (1) EP4263536A1 (enExample)
JP (1) JP7730369B2 (enExample)
KR (1) KR20230121830A (enExample)
CN (1) CN116848109B (enExample)
AU (1) AU2021404194A1 (enExample)
CA (1) CA3202054A1 (enExample)
CL (1) CL2023001755A1 (enExample)
CO (1) CO2023007838A2 (enExample)
CR (1) CR20230256A (enExample)
DO (1) DOP2023000125A (enExample)
EC (1) ECSP23044370A (enExample)
GB (1) GB202020191D0 (enExample)
IL (1) IL303484A (enExample)
JO (1) JOP20230128A1 (enExample)
MX (1) MX2023007140A (enExample)
PE (1) PE20240646A1 (enExample)
WO (1) WO2022129951A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104039321B (zh) 2011-11-18 2017-02-22 赫普泰雅治疗有限公司 药物化合物
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369184A (en) 1980-01-24 1983-01-18 Janssen Pharmaceutica N.V. 1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives
JPS56110674A (en) 1980-01-24 1981-09-01 Janssen Pharmaceutica Nv Novel 11*cyclohexyl**44aryll44piperidine carboxylic acid derivative
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
GB9300194D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
EP0786997A4 (en) 1994-10-27 1998-03-11 Merck & Co Inc MUSCARINE ANTAGONISTS
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
AU7478496A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine antagonists
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
AU3632297A (en) 1996-08-26 1998-03-19 Pfizer Inc. Spirocyclic dopamine receptor subtype ligands
WO1998057641A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
GB9715892D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
AU2095099A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparationand their use as muscarinic receptor (ant-)agonists
AU2307899A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO1999032489A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO1999032481A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
CZ286152B6 (cs) 1998-03-13 2000-01-12 Miroslav Ing. Csc. Vlček Transparentní a semitransparentní difrakční prvky
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
CZ301161B6 (cs) 1999-05-04 2009-11-18 Schering Corporation Piperidinopiperidylový derivát užitecný jako CCR5 antagonista, farmaceutický prostredek jej obsahující
PT1175224E (pt) 1999-05-04 2005-07-29 Schering Corp Terapeutica de combinacao contra hiv com interferao-alfa peguilado e um antagonista de ccr5
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
NZ518255A (en) 1999-09-13 2004-11-26 Boehringer Ingelheim Pharma Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
ES2223588T3 (es) 1999-10-13 2005-03-01 Banyu Pharmaceutical Co., Ltd. Derivados de imidazolidinona sustituidos.
US7163938B2 (en) 2000-11-28 2007-01-16 Eli Lilly And Company Substituted carboxamides
US7164024B2 (en) 2001-04-20 2007-01-16 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
WO2002100399A1 (en) 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
GB0128378D0 (en) 2001-11-27 2002-01-16 Smithkline Beecham Plc Novel Compounds
NZ533566A (en) 2001-12-28 2007-03-30 Acadia Pharm Inc Tetrahydroquinoline analogues as muscarinic agonists
US7550459B2 (en) 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
US7256186B2 (en) 2002-02-06 2007-08-14 Schering Corporation Gamma secretase inhibitors
US20040171614A1 (en) 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors
ATE454381T1 (de) 2002-03-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Benzofuranderivat
AU2003242252A1 (en) 2002-06-07 2003-12-22 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
WO2004014853A1 (en) 2002-07-31 2004-02-19 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
PT1551835E (pt) 2002-09-30 2007-03-30 Neurosearch As Novos derivados de 1, 4-diazabicicloalcano, sua preparação e utilização
RU2342388C2 (ru) 2002-11-22 2008-12-27 Джапан Тобакко Инк. Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием
PL376925A1 (pl) 2002-11-27 2006-01-09 Incyte Corporation Pochodne 3-aminopirolidyny jako modulatory receptorów chemokiny
JPWO2004069828A1 (ja) 2003-02-04 2006-05-25 三菱ウェルファーマ株式会社 ピペリジン化合物およびその医薬用途
EP1647553A4 (en) 2003-07-17 2008-12-31 Astellas Pharma Inc 2-ACYLAMINOTHIAZOL DERIVATIVE OR SALT THEREOF
US20070078120A1 (en) 2003-10-21 2007-04-05 Hitoshi Ban Novel piperidine derivative
CN1946402A (zh) 2004-02-05 2007-04-11 先灵公司 用作ccr3拮抗剂的哌啶衍生物
KR100863854B1 (ko) 2004-02-10 2008-10-15 에프. 호프만-라 로슈 아게 케모카인 ｃｃｒ5 수용체 조절제
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
JP2008521821A (ja) 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
JP4774995B2 (ja) 2005-01-12 2011-09-21 アステラス製薬株式会社 アシルアミノチアゾール誘導体を有効成分とする医薬組成物
WO2006105035A2 (en) 2005-03-28 2006-10-05 Vertex Pharmaceuticals Incorporated Muscarinic modulators
WO2006137485A1 (ja) 2005-06-24 2006-12-28 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
JP2009521483A (ja) 2005-12-22 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
TW200801008A (en) 2005-12-29 2008-01-01 Abbott Lab Protein kinase inhibitors
AU2007221214A1 (en) 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP1987034B1 (en) 2006-02-22 2011-07-20 Vertex Pharmceuticals Incorporated Spiro condensed piperidines as modulators of muscarinic receptors
AU2007284548A1 (en) 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
JP2010513357A (ja) 2006-12-22 2010-04-30 ノバルティス アーゲー Ｄｐｐ−ｉｖ阻害剤としての１−アミノメチル−１−フェニル−シクロヘキサン誘導体
WO2008117229A1 (en) 2007-03-23 2008-10-02 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
JP5564033B2 (ja) 2008-03-27 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの新規インヒビターとしてのアザ−ビシクロヘキシル置換インドリルアルキルアミノ誘導体
AU2009309988A1 (en) 2008-10-29 2010-05-06 Grunenthal Gmbh Substituted spiroamines
DK2379525T3 (en) 2008-12-19 2015-10-19 Boehringer Ingelheim Int Cyclic pyrimidin-4-carboxamides, as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD
NZ595432A (en) 2009-04-17 2013-12-20 Janssen Pharmaceutica Nv 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
FR2945531A1 (fr) 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
WO2011112825A2 (en) 2010-03-10 2011-09-15 Vanderbilt University Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective m1 agonists and methods of making and using same
JP2013525370A (ja) 2010-04-22 2013-06-20 ヤンセン ファーマシューティカ エヌ．ベー． ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物
EP2563127A4 (en) 2010-04-27 2013-11-06 Merck Sharp & Dohme PROLYLCARBOXYPEPTIDASE INHIBITORS
WO2011143057A1 (en) 2010-05-11 2011-11-17 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
EP2576520A1 (en) 2010-05-28 2013-04-10 GE Healthcare UK Limited Radiolabeled compounds and methods thereof
BR112013006344A2 (pt) 2010-09-17 2016-06-21 Array Biopharma Inc lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
EP2685828A4 (en) 2011-03-17 2014-08-13 Merck Sharp & Dohme SUBSTITUTED 3-AZABICYCLO [3,1,0-] HEXAN DERIVATIVES AS CCR2 ANTAGONISTS
JP2013010719A (ja) 2011-06-30 2013-01-17 Dainippon Sumitomo Pharma Co Ltd ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
CN104039321B (zh) 2011-11-18 2017-02-22 赫普泰雅治疗有限公司 药物化合物
DK2897948T3 (en) 2012-09-18 2016-12-05 Heptares Therapeutics Ltd BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS
CN105189482A (zh) 2013-02-07 2015-12-23 武田药品工业株式会社 作为毒蕈碱m4受体激动剂的哌啶-1-基羧酸酯和氮杂卓-1-基羧酸酯
EP3102568B1 (en) 2014-02-06 2018-06-27 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists.
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
PL3265459T3 (pl) 2015-02-13 2019-09-30 Suven Life Sciences Limited Związki amidowe jako agoniści receptora 5-HT4
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513740D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) * 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
US10259787B2 (en) 2016-10-14 2019-04-16 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
TW201922758A (zh) 2017-10-24 2019-06-16 美商歐樂根公司 烯胺及烯胺的非鏡像選擇性還原
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202103211D0 (en) 2021-03-08 2021-04-21 Heptares Therapeutics Ltd Pharmaceutical compounds for use in therapy

Also Published As

Publication number Publication date
CN116848109A (zh) 2023-10-03
PE20240646A1 (es) 2024-04-04
CL2023001755A1 (es) 2024-01-05
JOP20230128A1 (ar) 2023-06-06
CR20230256A (es) 2023-09-29
DOP2023000125A (es) 2023-08-31
EP4263536A1 (en) 2023-10-25
CN116848109B (zh) 2026-02-10
CA3202054A1 (en) 2022-06-23
ECSP23044370A (es) 2023-08-31
AU2021404194A1 (en) 2023-08-03
US20220380379A1 (en) 2022-12-01
CO2023007838A2 (es) 2023-10-30
WO2022129951A1 (en) 2022-06-23
IL303484A (en) 2023-08-01
KR20230121830A (ko) 2023-08-21
MX2023007140A (es) 2023-08-25
AU2021404194A9 (en) 2024-10-17
US11999745B2 (en) 2024-06-04
JP2024504252A (ja) 2024-01-31
JP7730369B2 (ja) 2025-08-27

Similar Documents

Publication Publication Date Title
GB201911928D0 (en) Pharmaceutical compounds
IL276232A (en) pharmaceutical compounds
GB201911944D0 (en) Pharmaceutical compounds
GB202010409D0 (en) Pharmaceutical compounds
GB202010408D0 (en) Pharmaceutical compounds
GB201810245D0 (en) Pharmaceutical compounds
GB201819961D0 (en) Pharmaceutical compounds
GB201915273D0 (en) Pharmaceutical compounds
GB201914910D0 (en) Pharmaceutical compounds
GB201810239D0 (en) Pharmaceutical compounds
GB201819960D0 (en) Pharmaceutical compounds
GB201915932D0 (en) Pharmaceutical compounds
GB201801562D0 (en) Pharmaceutical compounds
GB202111193D0 (en) Pharmaceutical compounds
GB202200753D0 (en) Pharmaceutical compounds
GB202104097D0 (en) Pharmaceutical compounds
IL291570A (en) Pharmaceutical preparations
GB201800378D0 (en) Pharmaceutical compounds
GB202102602D0 (en) Pharmaceutical compounds
GB202201283D0 (en) Pharmaceutical compounds
GB201816369D0 (en) Pharmaceutical compounds
GB202213819D0 (en) Pharmaceutical compound
GB202018068D0 (en) Pharmaceutical composition
GB202117969D0 (en) Pharmaceutical compounds
GB202007163D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)